NeuroScientific Biopharmaceuticals Limited (ASX:NSB) is an ASX-listed clinical-stage biopharmaceutical company focused on Research and Development of biomedical products targeting neurodegenerative conditions and immune-mediated inflammatory diseases. Following the Acquisition of the StemSmart™ mesenchymal stem cell (MSC) technology platform in June 2025, the company has made this its primary development focus.

Recent Developments

NeuroScientific reported a net loss of $4,693,164 for the year ended 30 June 2026, compared with a loss of $1,845,513 in FY25, as the company significantly increased R&D Investment following the StemSmart™ platform acquisition. Total income of $629,398 increased materially on the prior year, primarily due to a $402,659 Research and Development Tax Incentive receipt. On the clinical front, the company received notification that all patients in a small cohort treated with StemSmart™ through the TGA's Special Access Scheme for fistulising Crohn's disease showed improvement, with 4 of 5 achieving a successful clinical response — consistent with previous Phase 2 findings showing a 78 percent response rate in refractory Crohn's disease. Technology transfer of the StemSmart™ Manufacturing process to Q-Gen Cell Therapeutics is underway, with engineering runs supporting a TGA audit scheduled for October 2026 to expand Q-Gen's manufacturing licence ahead of Phase 2 trials in early CY 2027. Pre-IND meeting requests have been submitted to the FDA, and clinical research organisation evaluation is underway. The company has also decided not to continue independent development of EmtinB for glaucoma, instead pursuing out-licensing and strategic Partnership opportunities for the asset.

Sector Context

Cell therapy for immune-mediated inflammatory diseases, particularly Crohn's disease, is an active area of pharmaceutical development. Mesenchymal stem cells have demonstrated immunomodulatory properties and represent a potential treatment option for patients who have failed conventional and biologic therapies. The global Crohn's disease market is valued in the billions, with significant unmet need in the treatment-resistant segment that StemSmart™ targets.

Risk and Uncertainty

NeuroScientific is pre-revenue, with all commercial outcomes dependent on successful Phase 2 clinical trial results and subsequent regulatory approval — a pathway that typically takes many years and substantial capital. The SAS patient cohort providing positive signals was small, and these results, while encouraging, are insufficient to draw definitive clinical conclusions. The strategic decision to pursue out-licensing for EmtinB reduces the pipeline but also removes associated costs. Funding risk is present, given the growing loss and the expectation of further Capital raises to support Phase 2 activities.

Catalysts to Watch

The TGA audit of Q-Gen Cell Therapeutics in October 2026 — designed to expand their manufacturing licence for StemSmart™ — is an important near-term milestone paving the way for Phase 2 clinical manufacturing. Any FDA response to the pre-IND meeting request, and the formal announcement of the Phase 2 clinical trial protocol and CRO selection, will also be significant catalysts.

NeuroScientific Biopharmaceuticals is building the clinical and regulatory infrastructure for StemSmart™ Phase 2 trials in earnest, and the next six months — spanning the October TGA audit, FDA pre-IND engagement, and Phase 2 trial design finalisation — will be defining for the company's development trajectory.